BiotechTube
Cantargia

Cantargia

CANTA.ST
Lund, Sweden· Est.
cantargia.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Cantargia is a Nasdaq Stockholm-listed biotech focused on translating foundational research on the IL1RAP target into novel antibody therapies for cancer and inflammatory diseases. Its strategy centers on in-house development of candidates like nadunolimab (CAN04) to key value inflection points, followed by strategic partnerships for later-stage development and commercialization, as validated by the 2025 acquisition of its CAN10 program by Otsuka Pharmaceutical. The company's proprietary CANxx platform generates antibodies with a unique dual mechanism of action, positioning it to address significant unmet medical needs across multiple therapeutic areas.

OncologyInflammatory DiseasesAutoimmune Diseases

Technology Platform

Proprietary CANxx platform for generating monoclonal antibodies targeting IL1RAP, designed to deliver a dual mechanism of action: blocking IL-1/IL-33 signaling and inducing Antibody-Dependent Cellular Cytotoxicity (ADCC).

Opportunities

Cantargia's lead candidate, nadunolimab, addresses large, underserved oncology markets like pancreatic cancer and NSCLC.
The dual mechanism of its IL1RAP platform offers potential across both oncology and inflammatory diseases, creating multiple shots on goal and significant partnership potential.

Risk Factors

The company faces high clinical trial risk as its lead asset advances into late-stage studies.
As a pre-revenue firm, it remains dependent on capital markets and partnership deals to fund operations, posing dilution and execution risks.

Competitive Landscape

Direct competition in the IL1RAP space is limited but emerging. Cantargia differentiates with its antibody's dual signaling blockade and ADCC mechanism. Its primary competition in oncology is the current standard-of-care regimens, which nadunolimab aims to enhance in combination.

More companies in Sweden →